Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report

E-ISSN： 2050-0904|6|2|391-394

ISSN： 2050-0904

Source： Clinical Case Reports, Vol.6, Iss.2, 2018-02, pp. : 391-394

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sipuleucel-T in Metastatic Castration-Resistant Prostate Cancer†: Profile Report

By Plosker Greg L.

BioDrugs, Vol. 25, Iss. 4, 2011-08 ,pp. : 255-256

Adis International

Access to resources Recommend Favorite

Prostate cancer

Journal of Pain Management, Vol. , Iss. , 2017-01 ,pp. : 33-32

Nova Science Publishers, Inc.

Access to resources Recommend Favorite

Prostate cancer

Journal of Pain Management, Vol. , Iss. , 2017-01 ,pp. : 82-81

Nova Science Publishers, Inc.

Access to resources Recommend Favorite

Novel Prostate-Specific Promoter Derived from PSA and PSMA Enhancers

By Lee S.-J. Kim H.-S. Yu R. Lee K. Gardner T.A. Jung C. Jeng M.-H. Yeung F. Cheng L. Kao C.

Molecular Therapy, Vol. 6, Iss. 3, 2002-09 ,pp. : 415-421

Elsevier

Access to resources Recommend Favorite

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide

Clinical Case Reports, Vol. 3, Iss. 7, 2015-07 ,pp. : 551-552

John Wiley & Sons Inc

Access to resources Recommend Favorite